Point-of-care hemostatic test during TAVR procedure may help predict negative outcomes
1. Closure time with adenosine diphosphate (CT-ADP) measurement after a transcatheter aortic-valve replacement (TAVR) procedure was predictive of patients with...
Liraglutide associated with lower incidence of death from CV causes in type 2 diabetics
1. Patients with type 2 diabetes who received liraglutide were observed to have a significantly lower incidence of the composite...
Empagliflozin reduces the risk of long-term renal effects in type 2 diabetes
1. In patients with type 2 diabetes and an estimated glomerular filtration (eGFR) rate of ≥ 30 mL per minute...
Anti-IL-17A therapy linked to sustained improvement in plaque psoriasis: The UNCOVER trials
1. Patients with moderate-to-severe plaque psoriasis treated with ixekizumab had significantly greater improvements in psoriasis compared to those treated with...
Lower than expected seropositivity among vaccinated university students during N. meningitidis outbreak
1. In response to a meningococcal B outbreak at a US university in 2013 and 2014, the FDA approved the...
Extending adjuvant letrozole treatment may reduce breast cancer recurrence: The MA.17R trial
1. Extended-use adjuvant letrozole therapy was associated with significant reduction in breast cancer-free survival but not overall survival, compared to...
Olanzapine may reduce nausea symptoms for patients on chemotherapy
1. Olanzapine, in addition to 3 other anti-nausea agents, significantly reduced patient’s nausea over the first 120 hours following their...
No mortality difference between early and delayed renal replacement therapy: The AKIKI trial
1. Critically ill patients in the ICU with severe acute kidney injury (AKI) who were randomized to early renal replacement...
Catheter ablation more effective than antiarrythmic escalation for ventricular tachycardia: The VANISH trial
1. Catheter ablation was found to be more effective than escalated antiarrhythmic drug (AAD) therapy at treating patients with ischemic...
Adaptive treatment using neratinib shows benefit in early breast cancer
1. The addition of neratinib to standard therapy was more likely to result in higher pathological complete response rates compared...
